According to Zacks, “ReNeuron Group plc is involved in the development of cell-based therapies. Its therapeutic candidate is CTX stem cell therapy for the treatment of patients left disabled by the effects of a stroke which are in clinical development phase. ReNeuron Group plc is headquartered in Pencoed, the United Kingdom. “
Several other analysts have also recently commented on the stock. ValuEngine upgraded shares of ReNeuron Group from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 15th. Maxim Group reiterated a “buy” rating and issued a $6.00 price target on shares of ReNeuron Group in a research note on Thursday, September 12th.
Shares of ReNeuron Group stock opened at $1.65 on Thursday. The company has a fifty day moving average of $1.99 and a 200 day moving average of $2.72. ReNeuron Group has a fifty-two week low of $0.57 and a fifty-two week high of $4.43.
About ReNeuron Group
ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase II clinical trial for the treatment of patients living with chronic disability following stroke, as well as that has been completed Phase I clinical trial to treat limb ischaemia.
Recommended Story: Dividend Aristocrat Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ReNeuron Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group and related companies with MarketBeat.com's FREE daily email newsletter.